Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02353351
Other study ID # PS130046
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date January 19, 2015
Est. completion date February 24, 2017

Study information

Verified date January 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multicenter, case-cohort study.To identify potential risk factors associated with the occurrence of erosion due to implantation of the AMPLATZER™ Septal Occluder (ASO.)


Description:

This study will enroll 8000 subjects. The sub-cohort will consist of 160 (2%) subjects, randomly selected from the full cohort. The analysis population will consist of all subjects in the sub-cohort, combined with all subjects with erosion events who are not in the sub-cohort. A detailed assessment of risk factors will be conducted on the subjects in this analysis population.


Recruitment information / eligibility

Status Terminated
Enrollment 602
Est. completion date February 24, 2017
Est. primary completion date February 24, 2017
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

To participate in this clinical investigation, the patient must meet all of the following inclusion criteria:

1. Patient indicated for ASD closure who has echocardiographic evidence of ostium secundum atrial septal defect and clinical evidence of right ventricular volume overload (such as, 1.5:1 degree of left-to-right shunt or RV enlargement) and is implanted with the ASO device Note: This does not include the indication for closure of a fenestration following a fenestrated Fontan procedure

2. Patient is willing and able to complete the follow-up requirements of this study

3. Patient signs the informed consent (or a legal representative signs the informed consent.)

Exclusion Criteria:

Patient is not eligible for clinical investigation participation if he/she meets any of the following exclusion criteria:

1. Patient is known to have extensive congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery

2. Patient is known to have sepsis within 1 month prior to implantation, or any systemic infection that cannot be successfully treated prior to device placement

3. Patient is known to have a bleeding disorder, untreated ulcer, or any other contraindications to aspirin therapy (unless another anti-platelet agent can be administered for 6 months)

4. Patient is known to have a demonstrated intracardiac thrombus on echocardiography

5. Patient whose size (such as, too small for transesophageal echocardiography probe, catheter size) or condition (active infection, etc.) would cause the patient to be a poor candidate for cardiac catheterization

6. Patient has margins of defect that are less than 5 mm to the coronary sinus, AV valves or right upper lobe pulmonary vein

Study Design


Intervention

Device:
atrial septal occluder
Single arm atrial septal defect closure with the AMPLATZER Septal Occluder

Locations

Country Name City State
United States Albany Medical College Albany New York
United States Children's Healthcare of Atlanta Atlanta Georgia
United States North Austin Medical Center Austin Texas
United States University of Maryland Baltimore Maryland
United States University of Alabama Birmingham Alabama
United States Boston Children's Hospital Boston Massachusetts
United States Holy Spirit Hospital Camp Hill Pennsylvania
United States University of North Carolina Chapel Hill North Carolina
United States University of Virginia Charlottesville Virginia
United States Clearwater Cardiovascular Consultants Clearwater Florida
United States Cleveland Clinic Foundation Cleveland Ohio
United States Nationwide Children's Hospital Columbus Ohio
United States The Ohio State University Columbus Ohio
United States Driscoll Children's Hospital Corpus Christi Texas
United States Geisinger Medical Center Danville Pennsylvania
United States Children's Hospital of Michigan Detroit Michigan
United States Henry Ford Hospital Detroit Michigan
United States Duke University Hospital Durham North Carolina
United States Inova Fairfax Hospital Falls Church Virginia
United States East Carolina University Greenville North Carolina
United States Pinnacle Health Harrisburg Pennsylvania
United States Houston Methodist DeBakey Heart and Vascular Center Houston Texas
United States Texas Children's Hospital / Baylor College of Medicine Houston Texas
United States The University of Texas Health Science Center at Houston/Memorial Hermann Hospital Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States University of Mississippi Medical Center Jackson Mississippi
United States Baptist Medical Center Jacksonville Florida
United States Sunrise Hospital Las Vegas Nevada
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States University of Arkansas Little Rock Arkansas
United States Children's Hospital Los Angeles Los Angeles California
United States Kaiser Permanente Los Angeles Medical Center Los Angeles California
United States Ronald Reagan UCLA Medical Center Los Angeles California
United States University of Southern California Los Angeles California
United States Valley Children's Hospital Madera California
United States University of Wisconsin Madison Wisconsin
United States Aurora St. Luke's Medical Center Milwaukee Wisconsin
United States Children's Hospitals and Clinics of Minnesota Minneapolis Minnesota
United States Yale New Haven Hospital New Haven Connecticut
United States Cohen Children's Medical Center New Hyde Park New York
United States Children's Hospital New Orleans Louisiana
United States Children's Hospital of New York - Presbyterian New York New York
United States Mount Sinai Hospital New York New York
United States New York Presbyterian/Cornell New York New York
United States Advocate Christ Medical Center Oak Lawn Illinois
United States University of Oklahoma Oklahoma City Oklahoma
United States Arnold Palmer Hospital for Children Orlando Florida
United States Florida Hospital Orlando Orlando Florida
United States Stanford University Medical Center Palo Alto California
United States Huntington Memorial Hospital Pasadena California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States University of Pennslyvania Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh Pittsburgh Pennsylvania
United States St. Louis Children's Hospital Saint Louis Missouri
United States All Children's Hospital Saint Petersburg Florida
United States Primary Children's Hospital Salt Lake City Utah
United States Rady Children's Hospital San Diego California
United States Seattle Children's Hospital Seattle Washington
United States University of Washington Seattle Washington
United States Providence Medical Research Group Spokane Washington
United States Tampa General Hospital Tampa Florida
United States University of Arizona Tucson Arizona
United States Children's National Medical Center Washington District of Columbia
United States Iowa Heart Center / Mercy Medical Center West Des Moines Iowa
United States Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of cardiac erosion Cumulative incidence of erosion will be reported as:
• The number of erosions per 8000 subjects.
1 year
Secondary Aortic Rim Measurements (< 5 mm, = 5 mm) 1 year
Secondary Atrio-Ventricular (AV) Valve Rim Measurements (< 5 mm, = 5 mm) 1 year
Secondary Superior Vena Cava (SVC) Rim Measurements (< 5 mm, = 5 mm) 1 year
Secondary Inferior Vena Cava (IVC) Rim Measurements (< 5 mm, = 5 mm) 1 year
Secondary Other Evaluable Rim Measurements (< 5 mm, = 5 mm) 1 year
Secondary Ratio of Defect Size (Diameter) to Septal Length (< 0.5:1, = 0.5:1) 1 year
Secondary Ratio of Defect Size (Diameter) to Septal Width (< 0.5:1, = 0.5:1) 1 year
Secondary Device Splaying the Aorta (Yes, No) 1 year
Secondary Device Impingement of the Aorta (Yes, No) 1 year
Secondary Device Abutting the Aorta (Yes, No) 1 year
Secondary Age (< 14, = 14 years) 1 year
Secondary Gender (Male, Female) 1 year
Secondary Device Size Implanted (< 18 mm, = 18 mm) 1 year
Secondary Device Size to Defect Size (< 1.5:1, = 1.5:1) 1 year
Secondary Body Surface Area (<1.5 m2 and = 1.5m2) 1 year